-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B9c1WKETfruwlO4GyXsmo9A5VIy+tEu3pJzDn6Zm1WQcXa5bjswEN1JuRxi0KCnI n6OrrItOEMFwLzZC5zibtQ== 0001209191-10-031110.txt : 20100528 0001209191-10-031110.hdr.sgml : 20100528 20100528153823 ACCESSION NUMBER: 0001209191-10-031110 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100526 FILED AS OF DATE: 20100528 DATE AS OF CHANGE: 20100528 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLOAN GAIL A CENTRAL INDEX KEY: 0001237523 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 FILM NUMBER: 10866641 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 4365 EXECUTIVE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-05-26 0 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001237523 SLOAN GAIL A 4365 EXECUTIVE DRIVE, SUITE 300 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2010-05-26 4 A 0 94038 0.03 A 94038 D Series C-1 Convertible Preferred Stock 0.015 2010-05-26 4 A 0 22 1000.00 A 2010-12-03 Common Stock 1466674 22 D Series C-2 Convertible Pfd Stock Warrants (right to buy) 1000.00 2010-05-26 4 A 0 44 0.00 A 2010-05-26 2013-05-26 Series C-2 Convertible Preferred Stock 44 44 D Series D-1 Convertible Pfd Stock Warrants (right to buy) 1000.00 2010-05-26 4 A 0 22 0.00 A 2010-05-26 2013-05-26 Series D-1 Convertible Preferred Stock 22 22 D The Series C-1 Convertible Preferred Stock (the "Series C-1 Stock") is initially convertible into shares of common stock of La Jolla Pharmaceutical Company at a price per share of $0.015, but such conversion price will be adjusted for certain events, such as stock splits, stock dividends, reclassifications and recapitalizations, and is subject to full-ratchet anti-dilution protection such that any subsequent issuance of common stock below $0.015 automatically adjusts the conversion price of the Series C-1 Stock to such lower price. The Series C-1 Stock does not have a set expiration date, although the holders of such stock may require the Company to redeem the Series C-1 Stock upon certain events. Upon exercise of these Series C-2 Convertible Preferred Stock Warrants, Ms. Sloan will receive up to 44 shares of Series C-2 Convertible Preferred Stock and warrants to purchase up to 44 shares of Series D-2 Convertible Preferred Stock. /s/ Gail A. Sloan 2010-05-28 -----END PRIVACY-ENHANCED MESSAGE-----